Archives
-
Thiazovivin: Practical ROCK Inhibitor Workflow
2026-10-01
Thiazovivin (A5506) is a ROCK inhibitor for workflows involving fibroblast reprogramming, induced pluripotent stem cell generation, and human embryonic stem cell survival after trypsinization. This dossier-based guide covers preparation, controls, and troubleshooting; it does not establish a universal concentration or exposure schedule and is not intended for diagnostic or therapeutic use.
-
PEGylated Iron Oxide Nanoparticles in the Liver
2026-10-01
This ACS Nano study systematically separates the effects of iron oxide nanoparticle size and PEG chain length on hepatic biodistribution and cell-specific uptake. Its combination of 99mTc SPECT/CT imaging with primary liver cell experiments shows that hepatocytes and stellate cells can contribute substantially to uptake, challenging a Kupffer-cell-centered model of nanoparticle clearance.
-
AMPK–SQSTM1 Feedback in Metabolic Stress
2026-09-30
A 2024 Autophagy study identifies a double-positive feedback loop in which metabolic stress activates SQSTM1/p62, while AMPK activity reinforces SQSTM1 expression and phosphorylation. This circuit coordinates KEAP1 degradation, NRF2 activation, and lysosomal AMPK signaling, offering a mechanistic explanation for antioxidant adaptation in metabolically stressed tumor cells.
-
Isoprenaline Hydrochloride Assay Workflows
2026-09-30
Isoprenaline Hydrochloride, also known as isoproterenol, provides a controllable β-adrenergic challenge for cardiac, vascular, airway, and heart–brain experiments. This guide converts that pharmacology into practical workflows, protocol starting points, and troubleshooting decisions for reproducible research.
-
Deracoxib: From COX-2 Blockade to Tumor Assays
2026-09-29
Deracoxib is a selective COX-2 inhibitor whose value extends from pain and inflammation research to mechanistically resolved canine tumor assays. This article explains how concentration, exposure time, cell type, and orthogonal endpoints determine whether an observed response reflects cyclooxygenase-2 inhibition, apoptosis, or nonspecific cytotoxicity.
-
SNS-032: Reading CDK Biology Across Cancer and Virology
2026-09-29
SNS-032 (BMS-387032) is a research tool for dissecting CDK2, CDK7, and CDK9 biology through cell-cycle and RNA polymerase II readouts. This article connects its cancer evidence with a 2026 SARS-CoV-2 host-factor study while clearly separating demonstrated findings from testable hypotheses.
-
Sunitinib Workflow for RTK Cancer Research
2026-09-28
Build reproducible Sunitinib assays that connect VEGFR, PDGFR, c-kit, and RET blockade with angiogenesis, apoptosis, and cell-cycle readouts. This workflow also shows how phosphoproteomics can extend target-engagement studies without confusing viral kinase biology with cancer evidence.
-
Demethyleneberberine: Practical Research Workflows
2026-09-28
Demethyleneberberine (DMB) offers researchers a way to probe inflammatory signaling, mitochondrial control of IL-1β maturation, and selected cancer-model responses. This guide turns reported cell and animal model ranges into practical starting points, with formulation, assay-selection, and troubleshooting advice.
-
Chlorpromazine in Nanoparticle Assays: Limits and Logic
2026-09-27
Chlorpromazine can help frame pharmacological questions in nanoparticle assays, but it cannot by itself identify a particle-uptake mechanism. This article connects chlorpromazine research with a cell-resolved liver nanoparticle study while distinguishing evidence from testable hypotheses.
-
Sphingosine-1-phosphate: Reading Receptor Context
2026-09-26
Sphingosine-1-phosphate (S1P) can support vascular signaling yet promote neuronal apoptosis in a receptor- and model-dependent setting. This article examines a recent intracerebral hemorrhage study and explains how to interpret S1P experiments without treating the lipid as inherently pro-survival or pro-apoptotic.
-
Topotecan: Pharmacology and Clinical Evidence
2026-09-25
This 1999 review synthesizes topotecan’s pharmacology and early clinical experience, emphasizing its ability to stabilize the DNA–topoisomerase I cleavable complex and its activity in ovarian and small-cell lung cancers. It also highlights clinically relevant constraints—including marrow toxicity, renal elimination, and an incompletely defined dose–activity relationship—that inform experimental design and interpretation.
-
Tropisetron Hydrochloride in Transport Assays
2026-09-25
Use Tropisetron Hydrochloride to connect 5-HT3 receptor pharmacology with practical OCT2/MATE1 transporter studies. A published comparison of antiemetics offers a basis for assay selection, while the workflows here help distinguish receptor activity from transporter inhibition.
-
CCK-8 (cck8) for Bone Biomaterial Research
2026-09-24
See how CCK-8 can help evaluate osteoblast-like cell responses to mineralized collagen while avoiding a common error: treating absorbance as a direct cell count. This practical workflow covers controls for mineral particles, assay optimization, and how to interpret viability data alongside bone-regeneration endpoints.
-
Antiemetics Inhibit Renal OCT2 and MATE1 In Vitro
2026-09-24
George and colleagues compared five 5-HT3 antagonists in cell models of renal OCT2 and MATE1 transport, finding that inhibition varied by drug and transporter. Their results identify a potential mechanism for altered renal secretion of organic cations, while underscoring that cell-based inhibition alone does not establish a clinical drug interaction.
-
From RNA Delivery to Detection: Designing Better Probes
2026-09-23
Mechanistic studies of RNA delivery are only as useful as the assays that reveal their biological effects. Explore how fluorescent RNA probe design can strengthen gene-expression readouts, where Cy3 labeling fits, and how the HyperScribe™ T7 High Yield Cy3 RNA Labeling Kit supports ISH and Northern blot workflows.